Motilium (Domperidone)

Domperidone, the active ingredient in Motilium, is a dopamine D2 receptor antagonist presented as an oral dosage form for oral use. It treats nausea, vomiting and related gastrointestinal motility disorders in adults. GNH USA supplies Motilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Motilium is used to manage conditions affecting gastrointestinal motility and emesis. - Nausea and vomiting: reduces episodes by enhancing gastric emptying and blocking peripheral dopamine receptors. - Gastroparesis: improves gastric motility and alleviates associated symptoms such as early satiety and bloating. - Functional dyspepsia: lessens upper abdominal discomfort and improves meal tolerance.

Domperidone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Abdominal cramps: intermittent stomach pain. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Constipation or diarrhea: altered bowel habits. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Cardiac arrhythmia (QT prolongation): may lead to irregular heartbeat. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Extrapyramidal symptoms: rare movement disorders. - Hyperprolactinemia: elevated prolactin causing galactorrhea. - Hepatic dysfunction: abnormal liver enzymes. - Sudden cardiac death: extremely rare but reported in high‑dose or high‑risk patients.

Before prescribing Domperidone, clinicians should evaluate patient‑specific risk factors and follow safe handling practices. - Cardiac risk assessment: review ECG and QT interval in patients with known heart disease. - Concomitant CYP3A4 inhibitors: avoid or adjust therapy when strong inhibitors are used. - Hepatic impairment: use with caution and consider dose reduction. - Duration of therapy: limit to the shortest effective period to reduce adverse events. - Electrolyte monitoring: check potassium and magnesium in patients on diuretics or with renal disease. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Domperidone interacts with several drug classes that can modify its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase domperidone plasma concentrations and risk of cardiac toxicity. - QT‑prolonging agents (e.g., quinidine, sotalol): additive effect on cardiac repolarisation, raising arrhythmia risk.

Moderate Interactions (Monitor Closely):\n- Anticholinergic drugs: may exacerbate dry‑mouth side effect. - Other anti‑emetics (e.g., metoclopramide): overlapping mechanisms could increase adverse neurologic effects. - Electrolyte‑altering diuretics: may potentiate cardiac risk when combined with domperidone.